Wherever you sit in the partnership triangle, does it sound familiar? Many initiatives have tried to address this partnership ...
Tagrisso (osimertinib) has been approved by the US Food and Drug Administration (FDA) to treat a new subset of lung cancer ...
Picture this: a medicine targeting a particular disease is developed over 12-15 years from initial candidate selection, ...
Sanofi’s Sarclisa (isatuximab) has been approved by the US Food and Drug Administration (FDA) as part of a first-line ...
Eli Lilly and Almirall have announced positive long-term results for their targeted IL-13 inhibitor Ebglyss ...
The US Food and Drug Administration (FDA) has approved Zevra Therapeutics’ Miplyffa (arimoclomol) to treat Niemann-Pick ...
Sanofi has shared positive results from a late-stage study of its investigational BTK inhibitor, tolebrutinib, in patients ...
AMICULUM is delighted to have contributed to the MediaplanetUK Rare Diseases Campaign 2024, published in The Guardian on ...
Novo Nordisk and NanoVation Therapeutics have entered into a multi-year partnership worth $600m to advance genetic medicines ...
The European Commission (EC) has extended the marketing authorisation for Bavarian Nordic’s smallpox and mpox vaccine to ...
Less attention has been given to the impact AI can have at the later stages of drug development and on patient access. This ...
Daiichi Sankyo’s Vanflyta (quizartinib) has been recommended by the National Institute for Health and Care Excellence (NICE) for certain cases of acute myeloid leukaemia (AML). The drug has been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback